Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
J Clin Virol ; 122: 104231, 2020 01.
Article in English | MEDLINE | ID: mdl-31821950

ABSTRACT

BACKGROUND: There is limited data on the role of cytomegalovirus (CMV) blood quantitative polymerase chain reaction (qPCR) in the diagnostic workup of congenital CMV (cCMV) infection. OBJECTIVES: The objective of this study was to determine if CMV blood qPCR at the time diagnosis could differentiate between symptomatic and asymptomatic infants according to the recent consensus classification. STUDY DESIGN: Retrospective study of children diagnosed with cCMV infection at CHU Sainte-Justine, Montreal, Canada, between 2008 and 2016. Cases for whom qPCR was done at baseline (<4 weeks of age) alongside a complete diagnostic workup were included. The association between CMV blood viral load (VL) and clinical severity group was determined. The probability of having moderate to severe symptoms was assessed using univariate logistic regression analysis. RESULTS: Forty-seven patients were included in the analysis. Median VL was significantly higher among infants with moderate to severely symptomatic disease vs. those asymptomatic or asymptomatic with isolated sensorineural hearing loss (SNHL) (13 736 vs. 1876 copies/ml, p = 0.004), infants with moderate to severe disease or asymptomatic with isolated SNHL vs. asymptomatic (17 736 vs. 1496 copies/ml, p < 0.001), and in infants with baseline neurological involvement vs. those without (17 317 vs. 2641 copies/ml, p = 0.03). Using logistic regression, an infant would have a >75 % probability of being moderate to severely symptomatic above 18 770 copies/ml, with a threshold of 100 000 copies/ml approaching a 100 % probability. CONCLUSIONS: Our baseline assessment of CMV blood VL suggests that that the level of CMV viremia correlates with symptom severity.


Subject(s)
Cytomegalovirus Infections/blood , Cytomegalovirus Infections/diagnosis , Viral Load , Viremia/diagnosis , Asymptomatic Infections , Cytomegalovirus , Cytomegalovirus Infections/congenital , Hearing Loss, Sensorineural/virology , Humans , Infant, Newborn , Neonatal Screening , Real-Time Polymerase Chain Reaction , Retrospective Studies , Viremia/congenital
2.
Pediatr Dermatol ; 36(6): 869-875, 2019 Nov.
Article in English | MEDLINE | ID: mdl-31359495

ABSTRACT

BACKGROUND: Cutaneous patterned hypopigmentation's phenotype is highly variable and may be associated with extracutaneous anomalies. OBJECTIVE: We evaluated the phenotypic and clinical characteristics of patients with cutaneous patterned hypopigmentation to determine whether certain patterns were more likely to be associated with underlying anomalies. METHODS: The charts of 106 children with cutaneous patterned hypopigmentation were reviewed retrospectively (2007-2018) at Sainte-Justine University Hospital Centre, in Montreal, Canada. Retrieved information included sex, age at diagnosis, phototype, pattern, and distribution of the cutaneous lesions and the presence of extracutaneous findings. Data were recorded on a software tool which collects and analyzes phenotypic information. RESULTS: The predominant types of cutaneous patterned hypopigmentation were along Blaschko's lines in narrow (38.7%) and broad bands (53.8%). Mixed patterns were observed in 22.5% of children. The anterior trunk and posterior trunk were most frequently affected (69% and 56%, respectively). Extracutaneous involvement, especially neurological and developmental, was present in 28.3% of patients and was significantly associated with ≥ 4 involved body sites. CONCLUSION: Distribution and types of cutaneous patterned hypopigmentation were not predictive of extracutaneous findings, with the exception of multiple sites involvement and possibly centrofacial location and blocklike lesions. Follow-up until school entry should help identify subtler associated extracutaneous anomalies.


Subject(s)
Hypopigmentation/epidemiology , Child , Child, Preschool , Female , Humans , Hypopigmentation/congenital , Hypopigmentation/pathology , Infant , Infant, Newborn , Male , Phenotype , Quebec/epidemiology , Retrospective Studies
3.
Pediatr Dermatol ; 35(3): 323-328, 2018 May.
Article in English | MEDLINE | ID: mdl-29573445

ABSTRACT

BACKGROUND/OBJECTIVES: An increase in dermatophyte infections caused by African species is reported in countries receiving African immigrants. Our goal was to determine the epidemiologic and clinical characteristics of tinea capitis in children infected with African species of dermatophytes in Montreal, Canada. METHODS: Demographic and clinical data from medical records of children infected with African species of dermatophytes were retrieved retrospectively (2000-2016) at Sainte-Justine University Hospital Center. RESULTS: In Montreal, the number of tinea capitis cases caused by African species of dermatophytes increased sixfold over 17 years. African immigrant children (84%), men and boys (61%), and preschoolers (2-5 years old) (51%) were the most frequently affected in our 315 cases. Family contamination was frequent (45%). Referring physicians prescribed systemic antifungal treatment in 39% of cases and pediatric dermatologist consultants in 90%. Treatment failure to oral terbinafine occurred in 39% of Microsporum audouinii infections. CONCLUSION: In Montreal, there was a significant increase in tinea capitis caused by African species of dermatophytes. Microsporum audouinii is highly transmissible and often resistant to oral terbinafine. Recognizing tinea capitis trends in a given environment will improve patient care.


Subject(s)
Arthrodermataceae/isolation & purification , Tinea Capitis/epidemiology , Adolescent , Africa , Antifungal Agents/therapeutic use , Canada/epidemiology , Child , Child, Preschool , Emigrants and Immigrants , Female , Hospitals, Pediatric , Humans , Infant , Male , Retrospective Studies , Tinea Capitis/drug therapy , Tinea Capitis/microbiology
4.
BMC Pregnancy Childbirth ; 16: 54, 2016 Mar 15.
Article in English | MEDLINE | ID: mdl-26979058

ABSTRACT

BACKGROUND: Advances in diagnostic and therapeutic modalities for congenital cytomegalovirus (CMV) infection have generated a mounting interest in identifying mothers susceptible to CMV. The objectives of this study were to evaluate the prevalence and socio-demographic determinants of CMV susceptibility and CMV awareness, among pregnant women, in Montreal, Quebec. METHODS: Between April and December 2012, women delivering at Centre Hospitalier Universitaire Sainte Justine were recruited for the study. Stored serum from the first trimester of pregnancy was tested for CMV IgG. Knowledge about CMV and socio-demographic characteristics were collected via standardized questionnaire. RESULTS: Four hundred and ninety one women were enrolled in the study. Overall, 225 mothers (46%) were seronegative for CMV, and 85% (n = 415) were unaware of CMV or the associated risks in pregnancy. Significant risk factors for CMV seronegative status included Canadian vs. foreign born (aOR 6.88, 95% CI 4.33-10.94), and high vs. low family income (aOR 4.68, 95% CI 2.09-10.48). Maternal employment status was the only significant predictor of CMV unawareness, with unemployed mothers at the highest risk (aOR 85.6, 95% CI 17.3-421.3). CONCLUSIONS: Nearly half of pregnant women studied were at risk of primary infection, and yet, the majority was unaware of potential risks associated with CMV. Canadian born mothers and those with a high socioeconomic status were more likely to be CMV seronegative. Increased education about CMV infection, through public health interventions and obstetrician/pediatric counseling, is needed for all pregnant women.


Subject(s)
Cytomegalovirus Infections/epidemiology , Cytomegalovirus , Health Knowledge, Attitudes, Practice , Pregnancy Complications, Infectious/epidemiology , Pregnant Women/psychology , Adolescent , Adult , Cytomegalovirus Infections/psychology , Cytomegalovirus Infections/virology , Female , Humans , Immunoglobulin G/blood , Pregnancy , Pregnancy Complications, Infectious/psychology , Pregnancy Complications, Infectious/virology , Pregnancy Trimester, First/blood , Quebec/epidemiology , Risk Factors , Seroepidemiologic Studies , Young Adult
5.
J Int AIDS Soc ; 19(1): 20520, 2016.
Article in English | MEDLINE | ID: mdl-26880241

ABSTRACT

INTRODUCTION: The optimal management of infants born to HIV-positive mothers who are untreated or have detectable viral load prior to delivery remains controversial. Despite the increasing use of combination antiretroviral therapy (cART) for post-exposure prophylaxis (PEP) of neonates at high risk of HIV infection, there is little safety and pharmacokinetic data to support this approach. The objective of this study was to evaluate the safety and tolerability of cART for PEP in HIV-exposed neonates. METHODS: Retrospective study on 148 cART and 145 Zidovudine (ZDV) monotherapy-exposed infants identified from four Canadian centres where cART for PEP has routinely been prescribed in high-risk situations. Physician-reported adverse events and clinical outcomes were extracted by chart review. Haematological and growth parameters at birth, one and six months of age were compared between cART and ZDV-exposed infants using multivariate mixed effects modelling. RESULTS: Non-specific signs and symptoms were reported in 10.2% of cART recipients versus none of the ZDV recipients. Treatment was discontinued prematurely in 9.5% of cART recipients versus 2.1% of ZDV recipients (p=0.01). In the multivariate model, cART recipients had lower mean haemoglobin (decrease of 2.07 g/L) over the 6-month period compared with ZDV recipients (p=0.04), but no effect was seen on absolute neutrophil count. cART recipients had lower weight and smaller head circumference at birth and one month of age compared with ZDV-exposed infants; these differences were no longer significant at six months of age. CONCLUSIONS: cART administered at treatment doses for PEP in neonates was generally well tolerated, though a higher incidence of non-specific signs and symptoms and early treatment discontinuation occurred among cART recipients.


Subject(s)
Anti-HIV Agents/administration & dosage , HIV Infections/prevention & control , Infectious Disease Transmission, Vertical/prevention & control , Adult , Anti-HIV Agents/adverse effects , Canada , Drug Therapy, Combination , Female , Humans , Infant, Newborn , Male , Pregnancy , Retrospective Studies
6.
Can J Public Health ; 105(4): e268-72, 2014 May 30.
Article in English | MEDLINE | ID: mdl-25166129

ABSTRACT

OBJECTIVES: Pneumococcal infections constitute an important public health problem in Nordic regions of Canada. Nordic populations are not included in national and provincial immunization surveys and there is no centralized immunization registry in these regions. The objective of this study was to estimate pneumococcal vaccination coverage and delays in immunization of children in Nunavik, Quebec. METHODS: Immunization records of children born in 1994-2005 were collected in all villages. Children were classified into three groups: born in the period January 1, 1994 to April 30, 1997 and targeted by the 2002 mass campaign with the 23-valent polysaccharide vaccine (PPSV23); born in the period May 1, 1997 to March 31, 2002 and targeted by the 7-valent conjugate vaccine (PCV7) catch-up campaign; born in the period April 1, 2002 to December 31, 2005 and targeted by the PCV7 routine infant program. RESULTS: In the first group (n=896), 86.8% (95% CI: 84.4%-89.0%) were vaccinated with PPSV23. In the second group (n=1,252), 84.3% (95% CI: 82.1%-86.2%) received ≥1 PCV7 dose. In the third group, 90.4% (95% CI: 88.5%-92.1%) received 4 PCV7 doses. Delays >4 weeks in vaccine administration were observed for 26.3% of doses. There were substantial variations between villages for all indicators. CONCLUSIONS: In the challenging setting of a Nordic and remote region, uptake rates of pneumococcal vaccines in Nunavik were found to be similar to those measured in population surveys in Quebec.


Subject(s)
Immunization Schedule , Immunization/statistics & numerical data , Inuit/statistics & numerical data , Pneumococcal Infections/prevention & control , Pneumococcal Vaccines/administration & dosage , Child, Preschool , Female , Humans , Immunization Programs , Infant , Male , Quebec , Registries , Retrospective Studies , Vaccines, Conjugate
7.
Int J Circumpolar Health ; 73: 22691, 2014.
Article in English | MEDLINE | ID: mdl-24455492

ABSTRACT

BACKGROUND: In 2000, an outbreak of severe pneumonia caused by a virulent clone of serotype 1 Streptococcus pneumoniae was detected in the Nunavik region of Quebec. A mass immunization campaign was implemented in the spring of 2002, targeting persons ≥5 years of age and using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). At the same time, the 7-valent pneumococcal conjugate vaccine (PCV7) was introduced into the routine immunization programme of infants, with catch-up for children up to 4 years of age. OBJECTIVES: To describe the epidemiology of invasive pneumococcal disease (IPD) in relation to PPSV23 and PCV7 use. STUDY DESIGN AND METHODS: Retrospective analysis of IPD cases identified by the Quebec public health laboratory during the period 1997-2010. RESULTS: A total of 82 IPD cases were identified during the study period. In adults, serotype 1 incidence decreased following the 2002 PPSV23 mass campaign but breakthrough cases continued to occur. Following PCV7 use in children, there was a decrease in the incidence of vaccine-type IPD and replacement by other serotypes in adults. In children, a marked decrease in the annual incidence of serotypes included in PCV7 was observed following PCV7 introduction: 162/100,000 in 1997-2001 vs. 10/100,000 in 2004-2010 (p<0.01). Concomitantly, the incidence of IPD caused by serotypes not included in PCV7 increased from 29/100,000 to 109/100,000 (p=0.11). CONCLUSION: The mass immunization campaign using the PPSV23 in 2002 and the introduction of PCV7 for the routine immunization of infants induced important modifications in the epidemiology of IPD. IPD rates in Nunavik remain much higher than in the southern part of the province both in children and adults. More effective pneumococcal vaccines are needed to eliminate geographic disparities in IPD risk.


Subject(s)
Disease Outbreaks/prevention & control , Pneumococcal Vaccines/administration & dosage , Pneumonia, Pneumococcal/prevention & control , Public Health , Vaccination/methods , Age Factors , Cohort Studies , Female , Humans , Incidence , Inuit , Male , Pneumococcal Infections/epidemiology , Pneumococcal Infections/prevention & control , Pneumonia, Pneumococcal/epidemiology , Quebec/epidemiology , Registries , Retrospective Studies , Risk Assessment , Sex Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...